Get the Stockscreener App
20.67
2.38%
0.48
After Hours:
20.59
-0.08
-0.39%
Alto Neuroscience Inc stock is traded at $20.67, with a volume of 186.07K.
It is up +2.38% in the last 24 hours and up +8.85% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$20.19
Open:
$20.05
24h Volume:
186.07K
Relative Volume:
0.69
Market Cap:
$660.31M
Revenue:
-
Net Income/Loss:
$-63.24M
P/E Ratio:
-9.2075
EPS:
-2.2449
Net Cash Flow:
$-51.79M
1W Performance:
-8.21%
1M Performance:
+8.85%
6M Performance:
+443.95%
1Y Performance:
+717.00%
1-Day Range:
$19.98
$21.12
1-Week Range:
$19.41
$22.52
52-Week Range:
$1.60
$25.17
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
20.67 | 644.98M | 0 | -63.24M | -51.79M | -2.2449 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-17-25 | Initiated | BTIG Research | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
Alto Plunges 8.96% Despite Bullish Technicals - Bitget
Alto Neuroscience (NYSE:ANRO) Trading Down 5.5%What's Next? - MarketBeat
Alto Neuroscience CFO Nick Smith on Firm’s $120 Million Private Placement - Yahoo Finance
NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207 - Investing News Network
Alto Neuroscience, Inc.(NYSE: ANRO) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
If You Invested $1,000 in Alto Neuroscienc (ANRO) - Stock Titan
Alto Neuroscience (NYSE:ANRO) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Alto Neuroscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Johnson & Johnson (JNJ) and InspireMD (NSPR) - The Globe and Mail
HC Wainwright Issues Negative Estimate for ANRO Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Conmed (CNMD), Alto Neuroscience, Inc. (ANRO) and Pfizer (PFE) - The Globe and Mail
Alto Neuroscience Inc expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Alto Neuroscience (NYSE:ANRO) Stock Price Expected to Rise, Robert W. Baird Analyst Says - MarketBeat
H.C. Wainwright reiterates Alto Neuroscience stock rating at buy By Investing.com - Investing.com Canada
Stifel reiterates Buy on Alto Neuroscience stock, $33 target By Investing.com - Investing.com Australia
Stifel reiterates Buy on Alto Neuroscience stock, $33 target - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: Alto Neuroscience, Inc. (ANRO), Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Alto Neuroscience: Advancing Precision-Psychiatry Pipeline and De-Risked Trials Support Buy Rating - TipRanks
Alto Neuroscience (NYSE:ANRO) Stock Price Down 3.6%Time to Sell? - MarketBeat
ANRO: ALTO-207 advances in TRD with rapid titration, strong efficacy, and key pipeline catalysts ahead - TradingView
Chardan Capital Reiterates "Buy" Rating for Alto Neuroscience (NYSE:ANRO) - MarketBeat
Alto Neuroscience (NYSE:ANRO) Price Target Raised to $22.00 - MarketBeat
$120M financing supports Alto’s precision neuroscience approach to TRD - The Pharmaletter
Alto raises $120m for resistant depression programme - pharmaphorum
Alto Neuroscience raises $120M to fund depression drug trial By Investing.com - Investing.com South Africa
Alto Neuroscience Reports Strong 2025 Financials, Advances Precision Psychiatry Pipeline with ALTO-207 Acquisition and Key Clinical Milestones - Minichart
Alto Neuroscience Secures $120 Million Private Placement to Fund Phase 3 Study of ALTO-207 for Treatment Resistant Depression - Minichart
Targeting depression, Alto Neuroscience raises $120 million - The Business Journals
Watkins Advises on Alto Neuroscience’s US$120 Million Private Placement Financing - Latham & Watkins LLP
Alto Neuroscience 2025 Annual Report: Precision Psychiatry Platform, Clinical Pipeline, and Intellectual Property Overview - Minichart
Alto Neuroscience, Inc. announced that it expects to receive $119.99969 million in funding from a group of investors - marketscreener.com
Jefferies raises Alto Neuroscience stock price target on pipeline By Investing.com - Investing.com Canada
Alto Neuroscience (NYSE:ANRO) Sets New 1-Year HighHere's Why - MarketBeat
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum - marketscreener.com
Alto Neuroscience (ANRO) Reports FY25 Loss of $2.19/Share - AlphaStreet
Alto Neuroscience Announces $120 Million Private Placement Financing - TradingView
Alto Neuroscience raises $120M to fund depression drug trial - Investing.com
Alto Neuroscience Secures $120 Million Private Placement Financing - TipRanks
Alto Neuroscience (NYSE:ANRO) Posts Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
Alto Neuroscience (NYSE: ANRO) secures $120M PIPE to fund ALTO-207 - Stock Titan
ANRO: ALTO-207 acquisition and robust cash support multiple pivotal trials through 2028 - TradingView
Alto Neuroscience (NYSE: ANRO) outlines broad precision psychiatry pipeline and IP - Stock Titan
Alto Neuroscience 10-K: Net loss $63.24M, EPS $(2.19) - TradingView
Alto Neuroscience (NYSE: ANRO) posts 2025 loss but extends cash runway to 2028 - Stock Titan
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience (ANRO) to Release Quarterly Earnings on Thursday - MarketBeat
Alto Neuroscience (NYSE:ANRO) Trading 7.3% HigherWhat's Next? - MarketBeat
Alto Neuroscience Stock Pre-Market (-7.0%): Geopolitical Tensions Spark Risk-Off Move - Trefis
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
VSE Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday - Intellectia AI
Alto Neuroscience (NYSE:ANRO) Reaches New 52-Week HighWhat's Next? - MarketBeat
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):